NDATOPICALGEL
Approved
Dec 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
18
Data completeness
5/8 — Partial
FINACEA (azelaic acid) by Leo Pharma is mechanism(s) by which azelaic acid interferes with the pathogenic events in rosacea are unknown. Approved for papulopustular rosacea, acne vulgaris, rosacea. First approved in 2002.
Drug data last refreshed 23h ago
Mechanism of Action
mechanism(s) by which azelaic acid interferes with the pathogenic events in rosacea are unknown.
Indications (3)
Worked on FINACEA at Leo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.